All projects in this SPORE will use human specimens for translational research directed at reducing the incidence and mortality of pancreatic cancer. In order to provide the necessary specimens, a Pancreas Tumor SPORE Tissue Bank will be developed in cooperation with and under the auspices of the University of Nebraska Medical Center (UNMC) Tumor Bank. The guidelines and protocols for collecting specimens established by the UNMC Tumor Bank and the Institutional Review Board will be followed for the SPORE proposal. This core facility will store normal, benign (i.e. acute and/or chronic fibrosing pancreatitis) and malignant pancreatic tissues (including both primary and metastatic pancreatic carcinomas) and peripheral blood lymphocytes, plasma and serum from patients with pancreatic malignancies. The bank will also coordinate collection and storage of pancreatic ductal secretions and peritoneal washings. Cytogenetic analysis will be performed on all malignant lesions when possible. The core will include a mechanism for database management and specimen distribution. A uniform system of prioritization of requested materials would be defined and used by the Pancreas Tumor SPORE Tissues Bank oversight committee. This core facility is intended to benefit the specific research activities of the SPORE as well as the research activities of other scientists within and outside of UNMC who are concentrating on translational research issues. Additionally, tissues will be available for distribution through NCI supported tissue networks in national prioritization. Only specimens obtained from clinically indicated surgeries after all other diagnostic procedures have been performed will be submitted to the Pancreas Tumor SPORE Tissue Bank for translational research. The specimens would other wise be discarded or disposed of. Eligible patients will have the opportunity to participate by submitting written informed consent. There will be no risk to the patient or compromise to the patient's care, since all of the procedures performed would be performed for diagnostic reasons regardless of the SPORE. Members of the pathology department and the clinical departments are participants in the individual research projects and thus, also contribute to the Core for maximal and effective accumulation of satisfactory specimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA072712-03S4
Application #
6592172
Study Section
Project Start
1999-03-25
Project End
2003-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
2002
Total Cost
$201,603
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Chan, June M; Gong, Zhihong; Holly, Elizabeth A et al. (2013) Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 65:157-64
Mutolo, Michael J; Morris, Kirsten J; Leir, Shih-Hsing et al. (2012) Tumor suppression by collagen XV is independent of the restin domain. Matrix Biol 31:285-9
Pour, Parviz M (2012) A novel tissue for islet transplantation in diabetics. Pancreatology 12:57-60
Sherman, Simon; Shats, Oleg; Ketcham, Marsha A et al. (2011) PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform 10:83-91
Chan, June M; Wang, Furong; Holly, Elizabeth A (2009) Sweets, sweetened beverages, and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 20:835-46
Moniaux, Nicolas; Nemos, Christophe; Deb, Shonali et al. (2009) The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. PLoS One 4:e7077
Mimeault, M; Hauke, R; Batra, S K (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-91
Hennig, R; Osman, T; Esposito, I et al. (2008) BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer 99:1064-73
Davda, Jasmine P; Jain, Maneesh; Batra, Surinder K et al. (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-13
Hennig, Rene; Kehl, Timo; Noor, Seema et al. (2007) 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 9:917-26

Showing the most recent 10 out of 108 publications